Morgan Stanley lifts Keurig Dr Pepper stock rating, raises target

Published 01/04/2025, 05:12
Morgan Stanley lifts Keurig Dr Pepper stock rating, raises target

On Tuesday, Morgan Stanley (NYSE:MS)’s analysts upgraded Keurig Dr Pepper (NASDAQ:KDP) stock from ’Equalweight’ to ’Overweight,’ also increasing their price target from $38.00 to $40.00. Currently trading at $34.22, the stock sits below the average analyst target of $42.00. The firm’s analysis highlighted the company’s growth prospects, which they believe are not fully appreciated by the market. The analysts pointed to the strength in Keurig Dr Pepper’s US Refreshment segment and its solid international performance, despite short-term coffee profit risks. According to InvestingPro analysis, the company shows strong potential with multiple positive indicators available to subscribers.

The upgrade comes with an optimistic view of the company’s potential for corporate Operating Sales Growth (OSG) and Earnings Per Share (EPS) compared to its Consumer Packaged Goods (CPG) peers. Morgan Stanley noted that about 75% of the expected profit mix in 2025 is projected to come from these strong segments, up from 62% in 2021. This shift is seen as a significant factor in the company’s favor, supported by impressive gross profit margins of 55.56% and a strong overall financial health score as reported by InvestingPro.

The firm also emphasized Keurig Dr Pepper’s market share gains and pricing power within the US Refreshment category. They remarked on the company’s impressive first-quarter US scanner data, which showed a 460 basis point outperformance against large-cap peers. This was a substantial increase compared to a 160 basis point gap in the second half of 2024 and a 260 basis point gap in the first half of that year.

Looking ahead, Morgan Stanley analysts forecast that Keurig Dr Pepper’s OSG will improve to +70 basis points in 2025 compared to its large-cap peers, up from -150 basis points in 2024 and -290 basis points in 2023. They noted that this growth is not yet reflected in the company’s valuation, which remains nearly one standard deviation below its long-term average. With a P/E ratio of 32.34 and expected EPS growth, detailed valuation analysis is available through InvestingPro’s comprehensive research reports.

The analysis also positioned Keurig Dr Pepper as a potential "safe haven" in the event of a market downturn, citing its defensive business mix and minimal exposure to tariff and foreign exchange risks, although acknowledging some risk associated with the Supplemental Nutrition Assistance Program (SNAP). This defensive positioning is supported by a low beta of 0.63 and a consistent dividend growth record, with the company having raised its dividend for four consecutive years.

In other recent news, Keurig Dr Pepper has seen significant developments that could interest investors. The company recently completed a major public secondary offering, selling 73 million shares of common stock, which generated gross proceeds of approximately $2.7 billion. This transaction, led by J.P. Morgan Securities LLC, also included an option for the purchase of an additional 10.95 million shares. Following this sale, Keurig Dr Pepper announced the resignation of three board members affiliated with JAB Holding Company, reducing the board size from eleven to eight directors. The company emphasized that it did not receive proceeds from this sale, as the shares were sold by JAB BevCo B.V., a major shareholder.

Furthermore, analysts from Jefferies and Citi have shown optimism towards Keurig Dr Pepper’s future. Jefferies raised the price target for the company’s stock to $41, citing strong organic growth and earnings per share that exceeded expectations. Citi also increased its price target to $41, highlighting the company’s robust fourth-quarter performance and its alignment with growth projections. Both firms maintained a Buy rating on the stock, pointing to the company’s strategic commercial plans and innovation efforts as positive indicators for future sales growth.

Additionally, Keurig Dr Pepper is navigating potential regulatory challenges as a proposal to ban the purchase of soda with food stamps gains traction, which could impact sales. The American Beverage Association has opposed this initiative, emphasizing that soda is not the primary driver of obesity. These developments come amid a complex market environment, with the company facing potential cost pressures from rising coffee and aluminum prices. Despite these challenges, Keurig Dr Pepper remains committed to its growth strategy, with analysts expressing confidence in the company’s ability to achieve its projected earnings growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.